I have undertaken applied economic evaluations in primary care, inpatient and outpatient hospital settings, residential care and community pharmacies. I have particular expertise in the use of cost-effectiveness models to estimate costs and benefits over extended time horizons and have developed and published cost-effectiveness models in a wide range of clinical areas, including frailty, cardiovascular disease, ophthalmology and cancer screening.

My methodological research includes a longstanding interest in the use of simulation methods for health economic evaluation, including an invitation to chair an international working group on best practice in this area. Developed research methods to support improvements in model validation has also informed best practice guidelines. Recent research has estimated the opportunity costs of decisions to fund new technologies, which provides the first empirical estimate of the cost-effectiveness threshold in Australia €“ a critical input to funding decisions.

Jon has been developing methods and undertaking applied health economic evaluations for over 20 years with an increasing focus on the assessment of value across the health care system. He has experience in the use of Australian health systems data to compare the performance of hospitals and general practices, as well as to assess the value of alternative models of care. He is also familiar with the analysis of MBS and PBS data, as inputs to health services evaluations, as well as to investigate the cost effects of pharmaceutical pricing policies. He has particular expertise in the use of cost-effectiveness models and was a member of the most recent ISPOR taskforce on good modelling practice, chairing the discrete event simulation working group. In Australia, he has sat on the Economic Sub-Committee of the Pharmaceuticals Benefits Advisory Committee since 2009.